Article | October 22, 2021

An Expedited Development And Manufacturing Process To Support A COVID-19 Vaccine

By Kevin Thompson, Technical Director, Process Engineering Project Management Group, at Pall

iStock-1213713667-viral-vector-virus

Over the years, I’ve worked on countless projects with many customers – each one unique. But during the COVID-19 pandemic, we had the opportunity to work with the University of Oxford and AstraZeneca by supporting the rapid development and scale up of their COVID-19 vaccine, ChAdOx1-S /AZD1222 (now sold under the brand names Vaxzevira and COVISHIELD) – and that felt truly different. We joined a consortium led by the University of Oxford’s Jenner Institute to develop, scale up, and manufacture the vaccine. The process development and manufacturing work took place while clinical trials were still ongoing – typically, a huge risk, but one that was worth taking given the significant public health threat posed by SARS-CoV-2.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online